References
1. Spano F., Donovan J.C. Official Publication of The College of Family Physicians of Canada. Alopecia areata. Part 1: pathogenesis, diagnosis, and prognosis. Can Fam Physician. 2015; 61 (9): 751-5.
2. Gajigoroeva A.G. Clinical trichology. Moscow: Prakticheskaya Meditsina, 2014: 182 p. (in Russian)
3. Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol. 2013; 2013: 348546.
4. Rork J.F., Rashighi M., Harris J.E. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016; 28 (4): 463-9.
5. Mostafa W.Z., et al. Vitamin D and the skin: focus on a complex relationship: a review. J Adv Res. 2015; 6 (6): 793-804.
6. Bhat Y.J., Latif I., Sajad P Vitamin D level in alopecia areata. Indian J Dermatol. 2017; 62 (4): 407-10.
7. Gerkowicz A., Chyl-Surdacka K., Krasowska D., Chodorowska G. The role of vitamin D in non-scarring alopecia. Int J Mol Sci. 2017; 18 (12): 2653.
8. Wang J., Lv S., Chen G. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients. 2015; 7 (4): 248598.
9. Tan E., Tay Y.-K., Goh C.L. The pattern and profile of alopecia areata in Singapore - a study of 219 Asians. Int J Dermatol. 2002; 41: 74853.
10. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006; 20 (9): 1055-60.
11. Seyrafi H., Akhiani M., Abbasi H., Mirpour S. Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol. 2005; 5: 11.
12. Cunliffe W.J., Hall R., Stevenson C.J., Weightman D. Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol. 1969; 81: 87781.
13. Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011; 4: 107-15.
14. Paus R., Slominski A., Czarnetzki B.M. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol. Med. 1993; 66 (6): 541-4.
15. Gilhar A., Landau M., Assy B., Shalaginov R. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol. 2001; 117 (6): 1357-62.
16. Slominski A., Wotsman J., Luger T., Paus R., Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000; 80 (3): 979-1020.
17. Arck PC., Handjiski B., Peters E.M.J., et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003; 162 (3): 803-14.
18. Ito I., Ito T., Kromminga A., et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J. 2005; 19 (10): 1332-4.
19. Katsarou-Katsari A., Singh L.K., Theoharides T.C. Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress. Dermatology. 2001; 203 (2): 157-61.
20. Kim H.S., Cho D.H., Kim H.J., Lee J.Y., et al. Immunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone and melanocyte-stimulating hormone in alopecia areata. Exp Dermatol. 2006; 15 (7): 515-22.
21. Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann N Y Acad Sci. 2002; 966: 290-303.
22. Zhang X., Yu M., Yu W., Weinberg J., et al. Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3HHeJ mouse model. J Invest Dermatol. 2009; 129 (6): 1527-38.
23. Christoph T., et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol. 2000; 142 (5): 862-73.
24. Yokoyama W.M., et al. Licensing of natural killer cells by selfmajor histocompatibility complex class I. Immunol Rev. 2006; 214: 14354.
25. Mahamid M., Abu-Elhija O., Samamra M., Mahamid A., Nseir W. Association between vitamin D levels and alopecia areata. Isr Med Assoc J. 2014; 16 (6): 367-70.
26. d’Ovidio R., Vessio M., d’Ovidio F.D. Reduced level of 25-hydroxyvi-tamin D in chronic/relapsing alopecia areata. Dermatoendocrinology. 2013; 5 (2): 271-3.
27. Unal M., Gonulalan G. Serum vitamin D level is related to disease severity in pediatric alopecia areata. J Cosmet Dermatol. 2018; 17 (1): 101-4.
28. Kim D.H., Lee J.W., Kim I.S., Choi S.Y., Lim Y.Y., Kim H.M., et al. Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol. 2012; 24 (3): 341-4.
29. Lim Y.Y., Kim S.Y., Kim H.M., Li K.S., Kim M.N., Park K.C., et al. Potential relationship between the canonical Wnt signaling pathway and expression of the vitamin D receptor in alopecia. J Clin Exp Dermatol. 2014; 39 (3): 368-75.
30. Erpolat S., Sarifakioglu E., Ayyildiz A. 25-hydroxyvitamin D status in patients with alopecia areata. Postepy Dermatol Alergol. 2017; 34 (3): 248-52.
31. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J. 2001; 15 (14): 2579-85.